- Corporate Officers - G
- Gilead Sciences, Inc.
Insider Trading History of Gilead Sciences, Inc.
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Gilead Sciences, Inc. since 2021.
This trader's CIK number is 882095.
At the time of last reporting, Gilead Sciences, Inc. was the 10% Owner of Arcus Biosciences, Inc.. (stock ticker symbol RCUS).
Also see all insider trading activities at Arcus Biosciences, Inc..
Note that in the past
GILEAD SCIENCES, INC. also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Kyverna Therapeutics, Inc. (KYTX) by Gilead Sciences, Inc.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | KYTX | 910,000 | $20,020,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Assembly Biosciences, Inc. (ASMB) by Gilead Sciences, Inc.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | ASMB | 179,500 | $0 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Xilio Therapeutics, Inc. (XLO) by Gilead Sciences, Inc.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | XLO | 2,245,228 | $2,199,167 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Arcus Biosciences, Inc. (RCUS) by Gilead Sciences, Inc.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | RCUS | 1,363,636 | $14,999,996 | 0 | $0 | 0 | $0 |
| 2024 | RCUS | 15,238,095 | $319,999,995 | 0 | $0 | 0 | $0 |
| 2023 | RCUS | 1,010,000 | $19,452,600 | 0 | $0 | 0 | $0 |
| 2021 | RCUS | 5,650,000 | $220,350,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Allovir, Inc. (ALVR) by Gilead Sciences, Inc.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | ALVR | 2,930,870 | $10,990,762 | 0 | $0 | 0 | $0 |
Insider trading activities at 5 companies by Gilead Sciences, Inc.:
1. Kyverna Therapeutics, Inc. (KYTX)
2. Assembly Biosciences, Inc. (ASMB)
3. Xilio Therapeutics, Inc. (XLO)
4. Arcus Biosciences, Inc. (RCUS)
5. Allovir, Inc. (ALVR)
Table 1. Insider trading of Kyverna Therapeutics, Inc. (KYTX) by Gilead Sciences, Inc.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-02-12 | KYTX | Buy | 910,000 | 22.00 | 20,020,000 |
Table 2. Insider trading of Assembly Biosciences, Inc. (ASMB) by Gilead Sciences, Inc.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-06-17 | ASMB | Buy | 179,500 | .00 | 0 |
Table 3. Insider trading of Xilio Therapeutics, Inc. (XLO) by Gilead Sciences, Inc.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-12-18 | XLO | Buy | 1,759,978 | 1.04 | 1,830,377 |
| 2024-04-02 | XLO | Buy | 485,250 | .76 | 368,790 |
Table 4. Insider trading of Arcus Biosciences, Inc. (RCUS) by Gilead Sciences, Inc.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-02-18 | RCUS | Buy | 1,363,636 | 11.00 | 14,999,996 |
| 2024-01-29 | RCUS | Buy | 15,238,095 | 21.00 | 319,999,995 |
| 2023-06-28 | RCUS | Buy | 1,010,000 | 19.26 | 19,452,600 |
| 2021-01-31 | RCUS | Buy | 5,650,000 | 39.00 | 220,350,000 |
Table 5. Insider trading of Allovir, Inc. (ALVR) by Gilead Sciences, Inc.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-06-27 | ALVR | Buy | 2,930,870 | 3.75 | 10,990,762 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Gilead Sciences, Inc.
(10% Owner of Arcus Biosciences, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.